Supply Chain Logistics

Q&A explores new opportunities to strengthen supply chain resilience—and build on the lessons learned.

In an effort to strengthen supply chain, unnamed pharma company to use chain of custody application to combat an illegal global market worth up to $200 billion annually.

Stats point to a 14.9% decline compared to January of last year.

Factors to keep in mind before obtaining material in the cell therapy space.

Initiative intends to facilitate regulatory compliance within the pharma distribution space.

With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

Pharma sector, FMI report says, is quickly growing, due to globalization and development of low-cost medications.

Conclusion driven by various factors, including product shortages and cost pressures.

Meanwhile, PDG issues more DSCSA guidance on data interoperability.

Joint venture expected to address pharma’s injectable drug-filling sector.

Purchase doubles staffing, adds global capabilities.

Post-pandemic conditions are improving for the temperature-controlled market, but, meanwhile, the technical demands are rising.

How cell and gene therapies can be safely protected as they move along the supply chain, even when temperature-related challenges present themselves.

A conversation with Nico Ros, co-founder and CTO of SkyCell.

Outlining those advances poised to drive increased use of integrated tactical planning (ITP) in helping manufacturers overcome persistent supply chain obstacles.

Global air freight market data suggests only a 1.6% demand drop off compared to 2019.

Project—which is expected to double plant’s distribution capacity—will be completed by end of Q3.

Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.

A breakdown of how the industry is using these lessons to move full steam ahead.

Platform expected to allow customers to meet various logistics requirements, company says.

Reflects company’s identity and pharma supply chain impact

Cold chain company’s supply chain services experience to help facilitate therapy transport

Provider will be CDMO’s primary material supplier in the lab, clinical, and production settings

Global demand for advanced storage devices likely to fuel growth opportunities

Award given in recognition of CDMO’s commitment to promoting sustainable future

Phoenix location will be company’s first to focus on high-density microarrays for diagnostic and life science research

Action enables the company to begin offering its unit-load device for shipments

Statistics show a 13.7% decrease compared to November 2021.

Capacity is below 2021 levels

Provider’s regulatory affairs, pharmacovigilance services expected to help increase ABC’s portfolio